Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:HCN2-ALS2CR11

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: HCN2-ALS2CR11
	FusionPDB ID: 35781
	FusionGDB2.0 ID: 35781
		Hgene	Tgene
	Gene symbol	HCN2	ALS2CR11
	Gene ID	610	151254
	Gene name	hyperpolarization activated cyclic nucleotide gated potassium and sodium channel 2	C2 calcium dependent domain containing 6
	Synonyms	BCNG-2\|BCNG2\|HAC-1	ALS2CR11
	Cytomap	19p13.3	2q33.1
	Type of gene	protein-coding	protein-coding
	Description	potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2brain cyclic nucleotide-gated channel 2hyperpolarization activated cyclic nucleotide gated potassium channel 2	C2 calcium-dependent domain-containing protein 6amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 11amyotrophic lateral sclerosis 2 chromosomal region candidate gene 11 proteinamyotrophic lateral sclerosis 2 chromosome region cand
	Modification date	20200313	20200313
	UniProtAcc	Q9UL51 Main function of 5'-partner protein: FUNCTION: Hyperpolarization-activated ion channel exhibiting weak selectivity for potassium over sodium ions. Contributes to the native pacemaker currents in heart (If) and in neurons (Ih). Can also transport ammonium in the distal nephron. Produces a large instantaneous current. Modulated by intracellular chloride ions and pH; acidic pH shifts the activation to more negative voltages (By similarity). {ECO:0000250, ECO:0000269\|PubMed:10228147, ECO:0000269\|PubMed:10524219}.	.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000251287,	ENST00000450242, ENST00000482942, ENST00000286195, ENST00000439140, ENST00000439802,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	2 X 1 X 2=4	3 X 4 X 3=36
	# samples	2	4
	** MAII score	log2(2/4*10)=2.32192809488736	log2(4/36*10)=0.15200309344505 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0
Fusion gene context	PubMed: HCN2 [Title/Abstract] AND ALS2CR11 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: HCN2 [Title/Abstract] AND ALS2CR11 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	HCN2(590577)-ALS2CR11(202412333), # samples:2
Anticipated loss of major functional domain due to fusion event.	HCN2-ALS2CR11 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. HCN2-ALS2CR11 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. HCN2-ALS2CR11 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. HCN2-ALS2CR11 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	HCN2	GO:0071320	cellular response to cAMP	10228147\|22748890
Hgene	HCN2	GO:0071321	cellular response to cGMP	22748890
Hgene	HCN2	GO:0071805	potassium ion transmembrane transport	10228147
Hgene	HCN2	GO:0098719	sodium ion import across plasma membrane	10228147
Hgene	HCN2	GO:1990573	potassium ion import across plasma membrane	10228147

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr19:590577/chr2:202412333)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across HCN2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across ALS2CR11 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	Seq length (transcript)	BP loci (transcript)	Predicted start (transcript)	Predicted stop (transcript)	Seq length (amino acids)
ENST00000251287	HCN2	chr19	590577	+	ENST00000286195	ALS2CR11	chr2	202412333	-	1767	685	53	1579	508
ENST00000251287	HCN2	chr19	590577	+	ENST00000439802	ALS2CR11	chr2	202412333	-	1323	685	53	895	280
ENST00000251287	HCN2	chr19	590577	+	ENST00000439140	ALS2CR11	chr2	202412333	-	5175	685	53	5170	1705

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000251287	ENST00000286195	HCN2	chr19	590577	+	ALS2CR11	chr2	202412333	-	0.0045524	0.9954476
ENST00000251287	ENST00000439802	HCN2	chr19	590577	+	ALS2CR11	chr2	202412333	-	0.027212005	0.97278804
ENST00000251287	ENST00000439140	HCN2	chr19	590577	+	ALS2CR11	chr2	202412333	-	0.000229562	0.99977046

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for HCN2-ALS2CR11

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
HCN2	chr19	590577	ALS2CR11	chr2	202412333	685	207	RVKSAGAWIIHPYSDFRLEKMKKEYR

Top

Potential FusionNeoAntigen Information of HCN2-ALS2CR11 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

HCN2-ALS2CR11_590577_202412333.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-B35:03	HPYSDFRL	0.9865	0.8711	10	18
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-B35:02	HPYSDFRL	0.96	0.8964	10	18
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-B35:04	HPYSDFRL	0.96	0.8964	10	18
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-B38:02	IHPYSDFRL	0.9701	0.948	9	18
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-B38:01	IHPYSDFRL	0.9645	0.9334	9	18
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-A31:02	IIHPYSDFR	0.9362	0.5648	8	17
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-B15:37	IHPYSDFRL	0.7188	0.5701	9	18
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-B35:01	HPYSDFRLEKM	0.999	0.8142	10	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-B35:05	HPYSDFRLEKM	0.9985	0.5018	10	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-B35:03	HPYSDFRLEKM	0.9969	0.8541	10	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-B35:04	HPYSDFRLEKM	0.9891	0.9314	10	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-B35:02	HPYSDFRLEKM	0.9891	0.9314	10	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-B35:12	HPYSDFRL	0.96	0.8964	10	18
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-B39:10	HPYSDFRL	0.7469	0.9394	10	18
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C08:15	YSDFRLEKM	0.9999	0.9668	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C05:09	YSDFRLEKM	0.9999	0.8891	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C04:10	YSDFRLEKM	0.9999	0.8236	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C04:07	YSDFRLEKM	0.9999	0.8161	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C03:07	YSDFRLEKM	0.9981	0.9381	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C03:08	YSDFRLEKM	0.9981	0.8692	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C03:19	YSDFRLEKM	0.9978	0.9826	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C15:04	YSDFRLEKM	0.997	0.8354	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C01:30	YSDFRLEKM	0.9959	0.9449	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C15:06	YSDFRLEKM	0.9954	0.8718	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C04:06	YSDFRLEKM	0.9914	0.8592	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-B39:09	IHPYSDFRL	0.9903	0.5519	9	18
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-B39:05	IHPYSDFRL	0.97	0.8573	9	18
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C03:14	YSDFRLEKM	0.9667	0.9597	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C08:13	YSDFRLEKM	0.9655	0.9149	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C08:04	YSDFRLEKM	0.9655	0.9149	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-A31:01	IIHPYSDFR	0.9356	0.5392	8	17
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C04:14	YSDFRLEKM	0.9174	0.8528	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C08:03	YSDFRLEKM	0.8775	0.9623	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C07:13	IHPYSDFRL	0.3382	0.9073	9	18
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C07:29	IHPYSDFRL	0.3245	0.9115	9	18
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C02:06	YSDFRLEKM	0.2075	0.9101	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-B42:02	HPYSDFRLEKM	0.9904	0.6283	10	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-B35:12	HPYSDFRLEKM	0.9891	0.9314	10	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-B35:09	HPYSDFRL	0.96	0.8964	10	18
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-B67:01	HPYSDFRL	0.8575	0.7777	10	18
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C18:01	YSDFRLEKM	0.9999	0.8341	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C08:02	YSDFRLEKM	0.9999	0.9668	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C04:01	YSDFRLEKM	0.9999	0.8161	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C01:03	YSDFRLEKM	0.9999	0.9005	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C05:01	YSDFRLEKM	0.9999	0.8891	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C04:03	YSDFRLEKM	0.9999	0.831	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C03:03	YSDFRLEKM	0.9985	0.9804	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C03:04	YSDFRLEKM	0.9985	0.9804	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C03:02	YSDFRLEKM	0.9976	0.9421	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C15:09	YSDFRLEKM	0.997	0.8354	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C03:05	YSDFRLEKM	0.9958	0.9111	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C03:67	YSDFRLEKM	0.9956	0.9738	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C15:05	YSDFRLEKM	0.9938	0.8849	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C03:17	YSDFRLEKM	0.9933	0.944	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C15:02	YSDFRLEKM	0.9901	0.8449	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C04:04	YSDFRLEKM	0.9888	0.8684	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-B38:05	IHPYSDFRL	0.9645	0.9334	9	18
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C03:06	YSDFRLEKM	0.9401	0.9819	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C16:01	YSDFRLEKM	0.8842	0.9715	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C08:01	YSDFRLEKM	0.8775	0.9623	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C07:04	YSDFRLEKM	0.8752	0.9319	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C16:02	YSDFRLEKM	0.8487	0.9849	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C12:02	YSDFRLEKM	0.56	0.9455	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-B39:11	IHPYSDFRL	0.4339	0.7349	9	18
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C17:01	YSDFRLEKM	0.3226	0.7886	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C02:02	YSDFRLEKM	0.2026	0.9288	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-C02:10	YSDFRLEKM	0.2026	0.9288	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-B07:13	YSDFRLEKM	0.0033	0.7188	12	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-B35:77	HPYSDFRLEKM	0.999	0.8142	10	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-B35:30	HPYSDFRLEKM	0.9986	0.6679	10	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-B35:17	HPYSDFRLEKM	0.9986	0.6679	10	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-B55:04	HPYSDFRLEKM	0.9947	0.5111	10	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	HLA-B35:09	HPYSDFRLEKM	0.9891	0.9314	10	21

Top

Potential FusionNeoAntigen Information of HCN2-ALS2CR11 in HLA II

HCN2-ALS2CR11_590577_202412333.msa

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA II	FusionNeoAntigen peptide	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1501	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1501	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1501	WIIHPYSDFRLEKMK	7	22
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1501	AGAWIIHPYSDFRLE	4	19
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1502	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1502	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1503	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1503	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1503	AGAWIIHPYSDFRLE	4	19
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1503	WIIHPYSDFRLEKMK	7	22
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1504	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1504	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1504	AGAWIIHPYSDFRLE	4	19
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1504	WIIHPYSDFRLEKMK	7	22
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1505	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1505	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1505	WIIHPYSDFRLEKMK	7	22
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1505	AGAWIIHPYSDFRLE	4	19
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1506	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1506	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1506	WIIHPYSDFRLEKMK	7	22
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1506	AGAWIIHPYSDFRLE	4	19
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1507	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1507	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1507	AGAWIIHPYSDFRLE	4	19
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1507	WIIHPYSDFRLEKMK	7	22
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1508	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1508	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1509	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1509	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1509	WIIHPYSDFRLEKMK	7	22
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1509	AGAWIIHPYSDFRLE	4	19
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1510	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1510	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1510	WIIHPYSDFRLEKMK	7	22
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1510	AGAWIIHPYSDFRLE	4	19
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1511	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1511	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1512	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1512	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1512	AGAWIIHPYSDFRLE	4	19
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1512	WIIHPYSDFRLEKMK	7	22
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1513	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1513	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1513	WIIHPYSDFRLEKMK	7	22
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1513	AGAWIIHPYSDFRLE	4	19
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1514	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1514	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1515	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1515	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1516	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1516	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1516	WIIHPYSDFRLEKMK	7	22
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1516	AGAWIIHPYSDFRLE	4	19
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1518	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1518	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1518	WIIHPYSDFRLEKMK	7	22
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1518	AGAWIIHPYSDFRLE	4	19
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1519	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1519	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1520	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1520	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1520	WIIHPYSDFRLEKMK	7	22
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1520	AGAWIIHPYSDFRLE	4	19
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1521	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1521	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1521	WIIHPYSDFRLEKMK	7	22
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1521	AGAWIIHPYSDFRLE	4	19
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1522	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1522	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1522	WIIHPYSDFRLEKMK	7	22
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1522	AGAWIIHPYSDFRLE	4	19
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1523	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1523	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1523	AGAWIIHPYSDFRLE	4	19
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1524	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1524	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1524	WIIHPYSDFRLEKMK	7	22
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1524	AGAWIIHPYSDFRLE	4	19
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1525	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1525	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1526	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1526	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1528	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1528	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1528	WIIHPYSDFRLEKMK	7	22
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1528	AGAWIIHPYSDFRLE	4	19
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1529	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1529	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1529	AGAWIIHPYSDFRLE	4	19
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1529	WIIHPYSDFRLEKMK	7	22
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1530	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1530	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1530	AGAWIIHPYSDFRLE	4	19
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1530	WIIHPYSDFRLEKMK	7	22
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1531	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1531	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1532	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1532	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1532	WIIHPYSDFRLEKMK	7	22
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1532	AGAWIIHPYSDFRLE	4	19
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1533	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1533	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1533	WIIHPYSDFRLEKMK	7	22
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1533	AGAWIIHPYSDFRLE	4	19
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1535	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1535	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1535	WIIHPYSDFRLEKMK	7	22
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1535	AGAWIIHPYSDFRLE	4	19
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1536	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1536	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1536	AGAWIIHPYSDFRLE	4	19
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1536	WIIHPYSDFRLEKMK	7	22
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1537	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1537	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1537	AGAWIIHPYSDFRLE	4	19
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1537	WIIHPYSDFRLEKMK	7	22
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1538	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1538	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1539	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1539	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1540	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1540	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1540	WIIHPYSDFRLEKMK	7	22
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1540	AGAWIIHPYSDFRLE	4	19
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1541	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1541	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1541	WIIHPYSDFRLEKMK	7	22
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1541	AGAWIIHPYSDFRLE	4	19
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1542	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1542	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1542	WIIHPYSDFRLEKMK	7	22
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1542	AGAWIIHPYSDFRLE	4	19
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1543	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1543	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1543	WIIHPYSDFRLEKMK	7	22
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1543	AGAWIIHPYSDFRLE	4	19
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1544	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1544	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1545	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1545	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1545	WIIHPYSDFRLEKMK	7	22
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1545	AGAWIIHPYSDFRLE	4	19
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1546	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1546	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1546	WIIHPYSDFRLEKMK	7	22
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1546	AGAWIIHPYSDFRLE	4	19
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1547	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1547	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1548	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1548	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1548	AGAWIIHPYSDFRLE	4	19
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1548	WIIHPYSDFRLEKMK	7	22
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1549	GAWIIHPYSDFRLEK	5	20
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1549	AWIIHPYSDFRLEKM	6	21
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1549	AGAWIIHPYSDFRLE	4	19
HCN2-ALS2CR11	chr19	590577	chr2	202412333	685	DRB1-1549	WIIHPYSDFRLEKMK	7	22

Top

Fusion breakpoint peptide structures of HCN2-ALS2CR11

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
724	AWIIHPYSDFRLEK	HCN2	ALS2CR11	chr19	590577	chr2	202412333	685

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of HCN2-ALS2CR11

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	724	AWIIHPYSDFRLEK	-7.9962	-8.1096
HLA-B14:02	3BVN	724	AWIIHPYSDFRLEK	-5.70842	-6.74372
HLA-B52:01	3W39	724	AWIIHPYSDFRLEK	-6.83737	-6.95077
HLA-B52:01	3W39	724	AWIIHPYSDFRLEK	-4.4836	-5.5189
HLA-A11:01	4UQ2	724	AWIIHPYSDFRLEK	-10.0067	-10.1201
HLA-A11:01	4UQ2	724	AWIIHPYSDFRLEK	-9.03915	-10.0745
HLA-A24:02	5HGA	724	AWIIHPYSDFRLEK	-6.56204	-6.67544
HLA-A24:02	5HGA	724	AWIIHPYSDFRLEK	-5.42271	-6.45801
HLA-B44:05	3DX8	724	AWIIHPYSDFRLEK	-7.85648	-8.89178
HLA-B44:05	3DX8	724	AWIIHPYSDFRLEK	-5.3978	-5.5112
HLA-A02:01	6TDR	724	AWIIHPYSDFRLEK	-3.37154	-4.40684

Top

Vaccine Design for the FusionNeoAntigens of HCN2-ALS2CR11

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
HCN2-ALS2CR11	chr19	590577	chr2	202412333	10	18	HPYSDFRL	CGACTTCAGGCTGGAAAAGATGAA
HCN2-ALS2CR11	chr19	590577	chr2	202412333	10	21	HPYSDFRLEKM	CGACTTCAGGCTGGAAAAGATGAAAAAAGAATA
HCN2-ALS2CR11	chr19	590577	chr2	202412333	12	21	YSDFRLEKM	CAGGCTGGAAAAGATGAAAAAAGAATA
HCN2-ALS2CR11	chr19	590577	chr2	202412333	8	17	IIHPYSDFR	GTACAGCGACTTCAGGCTGGAAAAGAT
HCN2-ALS2CR11	chr19	590577	chr2	202412333	9	18	IHPYSDFRL	CAGCGACTTCAGGCTGGAAAAGATGAA

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide	FusionNEoAntigen RNA sequence
HCN2-ALS2CR11	chr19	590577	chr2	202412333	4	19	AGAWIIHPYSDFRLE	GATCATCCACCCGTACAGCGACTTCAGGCTGGAAAAGATGAAAAA
HCN2-ALS2CR11	chr19	590577	chr2	202412333	5	20	GAWIIHPYSDFRLEK	CATCCACCCGTACAGCGACTTCAGGCTGGAAAAGATGAAAAAAGA
HCN2-ALS2CR11	chr19	590577	chr2	202412333	6	21	AWIIHPYSDFRLEKM	CCACCCGTACAGCGACTTCAGGCTGGAAAAGATGAAAAAAGAATA
HCN2-ALS2CR11	chr19	590577	chr2	202412333	7	22	WIIHPYSDFRLEKMK	CCCGTACAGCGACTTCAGGCTGGAAAAGATGAAAAAAGAATATAG

Top

Information of the samples that have these potential fusion neoantigens of HCN2-ALS2CR11

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
CESC	HCN2-ALS2CR11	chr19	590577	ENST00000251287	chr2	202412333	ENST00000286195	TCGA-C5-A2LZ-01A

Top

Potential target of CAR-T therapy development for HCN2-ALS2CR11

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to HCN2-ALS2CR11

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to HCN2-ALS2CR11

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)